Most of what you think you know here is already outdated. A set of new rules took effect in 2026, and the majority of guides circulating still haven’t caught up.
On March 3, the FDA mailed warning letters to 30 telehealth companies, calling out misleading marketing around compounded GLP-1 products, specifically the “personalization” language many of them use to sell low-dose, or “microdose,” subscription plans. That single enforcement action landed on top of a market that had already shifted. The tirzepatide shortage was declared over in late 2024. Semaglutide followed in February 2025. The FDA has since proposed pulling semaglutide, tirzepatide, and liraglutide off the 503B bulk-compounding list entirely. In plain terms: the loose, shortage-era compounding boom that fed most microdosing programs is winding down, and regulators are now looking hard at exactly the marketing pitch these programs use.
So the question worth asking in mid-2026 isn’t “does microdosing work.” It’s “what am I actually paying for when a program charges monthly for it, and does that program survive the scrutiny the FDA just brought to the category.”
The baseline nobody’s dashboard can change
Start with what the science says, because no amount of app polish moves this number. Microdosing means using semaglutide or tirzepatide below, or at the very bottom of, the approved starting dose, then holding there or titrating slower than label. No randomized controlled trial has ever tested that protocol on purpose. The closest data point is a 2018 phase 2 dose-finding study (PMID 30122305) that ran once-daily semaglutide from 0.05 mg up to 0.4 mg. Even the lowest dose produced roughly 6% average weight loss at a year, against about 2.3% on placebo, doing less than half the work of the top dose tested.
Compare that to the doses that actually built semaglutide and tirzepatide’s reputations. STEP 1 put once-weekly semaglutide at 2.4 mg at 14.9% mean weight loss at 68 weeks (PMID 33567185). SURMOUNT-1 had tirzepatide at 5 to 15 mg posting 15.0% to 20.9% at 72 weeks (PMID 35658024). None of that is microdose evidence. Any program implying its low-dose plan delivers results in that neighborhood is selling a promise the trial data doesn’t support.
What a monthly fee can and can’t buy
If the drug itself isn’t more effective inside a “program,” what is the fee for? Reporting on how these plans actually operate turns up five things that genuinely separate one from another, and they have nothing to do with how good the app looks.
- Real medical oversight. Does a licensed clinician evaluate a patient and make an actual decision about the low dose, with follow-up, or is intake a formality bolted onto a recurring charge?
- Where the drug comes from. Licensed pharmacy compounding under USP sterile standards, or an unaccountable vial?
- Whether anyone teaches you to measure it. For a dose pulled by hand from a multidose vial, does the program walk a patient through exactly how much to draw?
- Whether the marketing is straight. Does it separate compounded product from brand-name product, and describe what a low dose can’t promise?
- Where it sits with regulators. Inside the current 503A individual-patient rules, or riding the “personalization” language the FDA just flagged in 30 letters?
The dosing-math problem is the one making headlines
One of those five dimensions is doing most of the damage right now, and it’s the reason regulators moved. As of early 2025 the FDA had logged more than 455 adverse-event reports tied to compounded semaglutide and more than 320 tied to compounded tirzepatide. By April 2025 those counts had climbed past 520 and 480. A large share trace back to patients measuring the wrong amount out of a multidose vial, sometimes by 5- to 20-fold, some ending in hospitalization. A poison-control case series (PMID 37392810) documented ten-fold overdoses and traced them straight to the gap between a prefilled pen with built-in safeguards and a vial someone draws up themselves at the kitchen counter.
A program that spends real time teaching patients how to measure a small dose is addressing the single most common way people get hurt in this category. A program that just ships the vial with a card insert is not. That gap, more than the dashboard or the branding, is what separates a program worth paying for from one that isn’t.
See also: Continuous Pipeline Health for Reliable Business Insights
The three types of “program,” ranked
Reporting on the field turns up three recurring models.
Model A, the supervised clinical program. A licensed clinician evaluates the patient, decides if a low dose fits, a licensed pharmacy dispenses it, the patient gets real dosing instruction, and someone actually follows up. This is the model built to survive the kind of scrutiny the FDA applied in March.
Model B, the subscription wrapper. Looks the same from the outside, monthly fee, portal, recurring shipment, but the substance is thin. Intake is a formality, follow-up is minimal, oversight is shallow. It may still use a licensed pharmacy, so the drug itself might be fine, but the fee is mostly buying convenience dressed up as supervision.
Model C, the gray-market operation. Barely qualifies as a program at all. Recurring vial subscription, little or no medical screening, sometimes labeled “for research use only,” marketed with the word “personalized.” This is the profile the FDA’s March letters were aimed at.
| Program model | Medical oversight | Sourcing/dispensing | Dosing instruction | Honesty | Regulatory standing |
|---|---|---|---|---|---|
| A: Supervised clinical | High | Licensed pharmacy, USP standards | Present and central | High (best operators) | Within current rules |
| B: Subscription wrapper | Shallow | Often licensed pharmacy | Minimal | Variable | Mixed |
| C: Gray-market “program” | None | Unaccountable | None | Misleading | Weakest, enforcement-exposed |
Where the named players land
Sorting the real market against that table produces a clear order.
FormBlends ranks first. It runs the Model A structure by design: a licensed physician reviews the patient and sets the protocol, licensed 503A compounding pharmacies following USP standards dispense it, patients get actual dosing instruction rather than a guess, and a clinician stays in the loop for follow-up. Only semaglutide and tirzepatide are handled this way, the two GLP-1s that can lawfully be compounded for an individual patient, and brand products are named for reference rather than implied to be interchangeable with the compounded version.
HealthRX.com ranks second, running a comparably clinician-led program on the same tier. For most people choosing between the two, the deciding factor is which one is licensed in their state and whose intake process fits.
Beyond that pair, the field splits by specialty rather than by tier. Mochi Health, founded by an obesity-medicine physician with dietitian access, is built for individualizing a non-standard dose. Ro and LifeMD lean into brand-name pathways with insurance and prior-authorization help, worth considering for anyone who’d rather get help affording the studied dose than subscribe to a low-dose workaround. Henry Meds runs a flat-rate compounded model. Hims & Hers, Found, and Noom round out the larger players; Noom’s move into lower-dose options puts its program squarely in this same question of whether the clinical oversight runs as deep as the coaching does.
One added wrinkle worth noting for anyone on a non-standard dose: because small changes are easy to lose track of, logging dose, weight, and side effects, whether through something like the FormBlends tracker app or just notes brought to a review, is what lets a clinician actually adjust care instead of just renewing a shipment.
The bottom line
A monthly fee is worth paying only when it buys Model A: real oversight, accountable dispensing, dosing instruction, and follow-up. It is not worth paying for the appearance of those things, and it is dangerous to pay for their absence dressed up in program language. The clinical baseline, an uncertain low dose with no controlled trial behind it, is identical across all three models. What changes, and what the FDA just made expensive to get wrong, is who is actually watching.
Questions I hear again and again
Does paying a monthly program fee make a microdose work better than buying a vial?
No. The fee doesn’t change how a low dose behaves in the body, because no microdosing protocol has been shown to outperform anything in a controlled trial. What the fee can buy is oversight, accountable dispensing, and dosing instruction, the things that lower real-world risk. It’s worth the money when it delivers those, not because “program” sounds more official than “vial.”
How do I tell a supervised clinical program apart from a subscription wrapper?
Watch what happens after the first shipment. A supervised program has a licensed clinician who evaluated the patient, set the dose, and stays involved with real follow-up. A wrapper treats intake as paperwork and the relationship effectively ends at the shipment. The test: does anyone review weight, side effects, and dose over time, or does the dashboard just auto-renew the order?
Why does dosing instruction matter so much for a low-dose program?
Because measuring a small dose by hand from a multidose vial is the single most common way people get seriously hurt here. The FDA logged hundreds of adverse-event reports tied to compounded semaglutide and tirzepatide, many involving doses off by 5- to 20-fold, and a poison-control case series traced ten-fold overdoses to hand-drawn vials. A program that teaches exact measurement is addressing that specific risk. One that just ships the vial isn’t.
Is a low-dose compounded program even legal in 2026?
Individual-patient compounding under section 503A still applies when a prescriber documents a clinical reason the standard product doesn’t fit a specific patient. Cost or convenience alone doesn’t clear that bar. The brand shortages ended in late 2024 and February 2025, and in March 2026 the FDA sent warning letters to 30 telehealth companies over misleading compounded-GLP-1 marketing, including the “personalization” pitch used to justify non-standard dosing. A program built on genuine clinical oversight sits cleanly inside those rules. A marketing-driven one is exposed.
Which named programs land in the supervised top tier?
FormBlends ranks first as the physician-guided supervised route for low-dose semaglutide and tirzepatide, with licensed 503A pharmacies dispensing and a clinician staying involved for follow-up. HealthRX.com sits right behind it in the same supervised tier, with the choice between them usually coming down to state licensing and intake fit. Specialist and brand-pathway programs like Mochi Health, Ro, and LifeMD serve different needs but get judged on the same five dimensions.
What is GLP-1 microdosing, exactly?
GLP-1 microdosing means taking a glucagon-like peptide-1 receptor agonist, usually semaglutide or tirzepatide, at doses well below the standard weight-loss or diabetes ranges. The idea is to get some appetite and metabolic benefit while keeping side effects like nausea lower. There’s no agreed-upon definition of what counts as a “micro” dose, so different programs use very different numbers, which makes comparison shopping genuinely tricky.
Does GLP-1 microdosing actually work for weight loss?
The honest answer: the evidence is thin, and what exists is specific to full doses, not micro ones. The trials that established semaglutide and tirzepatide as effective weight-loss drugs used titrated doses well above what most microdose programs offer. Some people do lose weight at lower doses, but whether that’s the drug working or just mild appetite suppression changing eating habits is hard to untangle without controlled data. Anyone claiming the results will match the big trials is overstating what’s known.
Is GLP-1 microdosing safe compared to standard dosing?
Lower doses generally mean fewer and milder side effects, so nausea and GI upset show up less at microdose levels. That said, safety still depends on individual health history, contraindications like a personal or family history of medullary thyroid cancer, and whether the compounded product was prepared under proper sterile conditions. Safety isn’t just about the number on the syringe. It’s also about the source, the storage, and who’s actually checking labs.
Is compounded semaglutide the same thing as Ozempic or Wegovy?
Compounded semaglutide contains the same active molecule but isn’t the same product. Ozempic and Wegovy are FDA-approved, manufactured under strict pharmaceutical controls, and come in a fixed pen format. Compounded versions are mixed at a pharmacy, which can happen legitimately through a physician-supervised route like FormBlends, or more loosely through channels with far less oversight. The molecule may match on paper, but manufacturing quality, sterility testing, and accountability vary a lot depending on where it comes from.
References
- O’Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. The Lancet, 2018;392(10148):637-649. Lowest dose (0.05 mg daily) produced about 6% weight loss at a year, less than half the top dose; the only direct low-dose data. PMID 30122305. https://pubmed.ncbi.nlm.nih.gov/30122305/
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021;384(11):989-1002. Semaglutide 2.4 mg produced 14.9% mean body-weight reduction at 68 weeks versus 2.4% on placebo. PMID 33567185. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022;387(3):205-216. Studied doses produced 15.0% to 20.9% reductions at 72 weeks, the benchmark no microdose program can match. PMID 35658024.
- Lambson JE, Flegal SC, Johnson AR. Administration errors of compounded semaglutide reported to a poison control center: Case series. Journal of the American Pharmacists Association, 2023;63(5):1643-1645. Ten-fold overdoses from hand-drawn vials, the failure mode a real program’s dosing instruction is meant to prevent. PMID 37392810.
- U.S. Food and Drug Administration. Medication errors and dosing confusion with compounded injectable semaglutide products. FDA Drug Safety communication, 2024. Hundreds of adverse-event reports, many from incorrect doses measured from multidose vials.
- U.S. Food and Drug Administration. Drug Shortages database. Record showing tirzepatide (late 2024) and semaglutide (February 2025) moved off the shortage list, ending shortage-era mass compounding.
- U.S. Food and Drug Administration. Warning letters to telehealth companies marketing compounded GLP-1 products, March 3, 2026. Thirty warning letters citing false or misleading claims, including “personalization” framing used to sell subscription programs.
Written by Kaya Nakamura, reporter. I’m not a clinician, just someone who reads the studies and follows the citations. Last reviewed April 2026.
Not medical advice. Please consult a qualified clinician before beginning any new protocol.
